IV Lidocaine in Pediatric AIS

PHASE4Enrolling by invitationINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

July 30, 2019

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Systemic Lidocaine Improves Pain Control After Surgery by Attenuating the Systemic Inflammatory Response to Surgery
Interventions
DRUG

IV lidocaine

an amide-type, short-acting local anesthetic and delivered as an aqueous solution for intravenous administration. It has a half-life of 1.5-2 hours. A traditional method of administration is via epidural delivery. Epidural lidocaine is effective and this effect is due, in part, to systemic absorption. Systemic (intravenous) administration of lidocaine is a Food and Drug Administration approved method of delivery. Low plasma levels are needed for effective use, 0.5µg/mL to 5.0µg/mL. Given this low concentration required and the short half-life, continuous infusion of lidocaine is thought to be generally safe with low risk of complication.

DRUG

Placebos

Saline

Trial Locations (1)

63108

Barnes Jewish Hospital and St. Louis Children Hospital / Washington University in St. Louis School of Medicine, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER